医学
脐血移植
移植
脐带
造血
造血干细胞移植
微小残留病
肿瘤科
急性白血病
干细胞
免疫学
造血细胞
白血病
内科学
生物
遗传学
作者
Mattia Algeri,Stefania Gaspari,Franco Locatelli
标识
DOI:10.1080/14712598.2020.1782380
摘要
Introduction Umbilical cord blood transplantation (UCBT) is a suitable alternative for patients with acute leukemia (AL) in need of an allograft and who lack an HLA-matched donor. Single-institution and registry studies have shown that, in both children and adults with AL, the outcome of UCBT is comparable to that of matched unrelated donor. At the same time, these studies have highlighted some limitations of UCBT, such as increased early mortality and delayed recovery of both hematopoietic and immune compartment, which hamper a more widespread adoption of this approach.Areas covered In this review, we will analyze the current results of UCBT in children and adults with AL, including comparisons with other hematopoietic stem cell sources and transplant strategies. We will also discuss important factors to be considered when selecting UCB units, as well as future strategies to further improve the outcome of UCBT recipients.Expert opinion The utilization of UCBT for the treatment of AL patients has decreased in recent years. However, recent clinical data suggesting that UCBT might offer better results in patients with minimal residual disease, as well as innovative strategies to facilitate engraftment, reduce transplant-related mortality, and optimize anti-leukemic activity, may pave the way toward a second youth for use of UCB cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI